These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 26337717)
1. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature. Molica S; Levato L; Mirabelli R Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717 [No Abstract] [Full Text] [Related]
2. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib. Poole A; Girard N; Clayton F; Tantravahi SK Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463 [No Abstract] [Full Text] [Related]
3. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy. Woyach JA Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693 [No Abstract] [Full Text] [Related]
4. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. Saenz-de-Viteri M; Cudrnak T Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238 [No Abstract] [Full Text] [Related]
5. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. Goldschmidt N; Rund D Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158 [No Abstract] [Full Text] [Related]
6. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia. Sato R; Jacob J; Gaballa S Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253 [No Abstract] [Full Text] [Related]
8. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603 [TBL] [Abstract][Full Text] [Related]
9. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246 [No Abstract] [Full Text] [Related]
10. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945 [TBL] [Abstract][Full Text] [Related]
11. Is HBV prophylaxis required during CLL treatment with ibrutinib? Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112 [No Abstract] [Full Text] [Related]
12. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216 [No Abstract] [Full Text] [Related]
13. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy. Wendtner CM Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694 [No Abstract] [Full Text] [Related]
14. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231 [No Abstract] [Full Text] [Related]
15. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Tam CS Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894 [No Abstract] [Full Text] [Related]
16. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572 [No Abstract] [Full Text] [Related]
17. The use of ibrutinib in chronic lymphocytic leukemia. Damon LE Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026 [No Abstract] [Full Text] [Related]
18. Ibrutinib: searching for a partner drug. Kater AP; Brown JR Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966 [No Abstract] [Full Text] [Related]
19. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins. Ambinder AJ; Hambley B; Shanbhag S; Merrill SA Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009 [No Abstract] [Full Text] [Related]
20. Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib. Tucker DL; Mihailescu L; Riordan R; Rule S Br J Haematol; 2017 Jul; 178(1):153-155. PubMed ID: 27172457 [No Abstract] [Full Text] [Related] [Next] [New Search]